On August 17, 2026, Femtech Insider reported that Kiara Health has closed an undisclosed pre-seed round from Coyote Ventures to build out its AI-powered personalized fertility care platform. The founding team is unusually inside-baseball: co-founder Milan Chavarkar is a nurse practitioner, founder of Lotus Health and a Limited Partner at Coyote; co-founder Priyanka Vaidya founded Delfina Health and is a Venture Partner at the same fund.

Why It Matters

Reproductive health has no shortage of point solutions — a tracker here, a lab panel there, an egg-freezing clinic somewhere else — and almost no connective tissue between them. Kiara is betting the value sits in the integration layer rather than any single data source, which is why the Mira/Levels/Natera partnerships matter more than the round size: they're the raw material for an engine nobody else is assembling in one place. The pre-treatment window is also the right commercial wedge. It's where patients are most uncertain, least served, and most likely to pay out of pocket — the same insight behind Sunfish Starts' six-month readiness program launched earlier this month and The American Baby Company's $8,995 IVF pricing play. A cluster of independent teams attacking the same pre-clinical gap is usually a sign the gap is real. The obvious caveat: a fund investing in a company co-founded by its own LP and its own Venture Partner is a tight circle, and an undisclosed pre-seed is the earliest and least informative signal in venture. Worth watching whether outside capital validates the thesis at seed. Also worth noting the contrast with Play Health, which shut down this same week after failing to find a reimbursement fit for menopause software — Kiara's employer-and-health-system framing suggests the team already knows that pure-consumer femtech software is the hard road.

The product is a "Fertility Intelligence Engine" that combines clinical history, lifestyle inputs, biomarkers, laboratory data and evidence-based guidelines to generate personalized insights and care plans. The target window is deliberately upstream of the clinic — helping patients understand their fertility options before entering treatment, which is where most of the confusion, cost anxiety and irreversible decision-making actually happens. Kiara has lined up data partnerships with Mira, Levels and Natera to feed the engine, which is a notable stack: hormone tracking, metabolic data and genetic screening respectively.

Coyote founder and managing partner Jessica Karr framed the thesis around fragmentation. "Kiara addresses this fragmentation by creating a unified intelligence platform that translates complex reproductive health data into personalized recommendations that evolve," she wrote. "Instead of asking patients to navigate dozens of disconnected decisions, Kiara provides a coordinated pathway that spans education, diagnostics, coaching, clinical care, and ongoing optimization."

The stated ambition runs well past fertility. "What begins as fertility intelligence can ultimately evolve into a longitudinal reproductive health platform spanning fertility optimization, IVF preparation, pregnancy risk prediction, maternal health, postpartum care, and menopause," Karr said, describing an engine that keeps learning across reproductive life stages while serving clinicians, researchers, employers and health systems. Round size was not disclosed.

Sources

Update — 2026-08-18

Initial entry — story first created.